Cryo-Cell International, Inc.: updates and filings

CCELAMEXHealthcare · Services-Misc Health & Allied Services, NEC

Price

$4.48

November 16, 2026Market cap $36M

What Ploutos Investor adds for Cryo-Cell International

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 16 fiscal years, from FY2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 59 daysAround Jan 14, 2027 · for Q4 2026

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 27, 2026 latest annualOct 9, 2026 latest quarterly
  • Oct 28, 2026Shareholder vote
    Form8-K
  • Oct 13, 2026Annual meeting proxy statement
    FormDEF 14A
  • Oct 13, 2026Annual report to shareholdersfor the period to Nov 30, 2025
    FormARS
  • Oct 9, 2026Quarterly reportfor the period to Aug 31, 2026
    Form10-Q
  • Sep 14, 2026Other material events
    Form8-K
  • Jul 15, 2026Quarterly reportfor the period to May 31, 2026
    Form10-Q
  • Jul 7, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • May 8, 2026Delisting notice, Regulation FD disclosure
    Form8-K
  • Apr 14, 2026Quarterly reportfor the period to Feb 28, 2026
    Form10-Q
  • Mar 25, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • Mar 12, 2026Delisting notice, Regulation FD disclosure
    Form8-K
  • Feb 27, 2026Annual reportfor the period to Nov 30, 2025
    Form10-K
  • Nov 12, 2025Other material events
    Form8-K
  • Oct 23, 2025Material agreement entered, new material financial obligation
    Form8-K
  • Oct 15, 2025Quarterly reportfor the period to Aug 31, 2025
    Form10-Q
  • Sep 26, 2025Annual meeting proxy statement
    FormDEF 14A
  • Sep 26, 2025Annual report to shareholdersfor the period to Nov 30, 2024
    FormARS
  • Sep 10, 2025Other material events
    Form8-K
  • Jul 15, 2025Quarterly reportfor the period to May 31, 2025
    Form10-Q
  • May 22, 2025Material agreement ended
    Form8-K
  • May 8, 2025Other material events
    Form8-K
  • Apr 14, 2025Quarterly reportfor the period to Feb 28, 2025
    Form10-Q
  • Feb 28, 2025Annual reportfor the period to Nov 30, 2024
    Form10-K
  • Dec 27, 2024Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 12, 2024Shares registered for employees
    FormS-8

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Feb 28, 1997.

The full analysis

What do Cryo-Cell International's filings show?

The filings are where every one of Cryo-Cell International's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.